Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 11/20 | 0.67 |
| ▸ | VDAC2 | P45880 | 1/20 | 0.64 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.64 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.58 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12610101 | 0.89 | VDAC2 (0.68) | HIF1AVDAC2SLC7A11CACNA2D1HTR7 | |
| SCHEMBL12610306 | 0.89 | VDAC2 (0.61) | HIF1AVDAC2SLC7A11CACNA2D1HTR7 | |
| SCHEMBL4457790 | 0.89 | CACNA2D1 (0.61) | HIF1AVDAC2SLC7A11CACNA2D1ALDH1A1 | |
| SCHEMBL13789539 | 0.89 | HIF1A (0.55) | HIF1AVDAC2SLC7A11CACNA2D1LMNA | |
| SCHEMBL4456445 | 0.87 | HIF1A (0.51) | HIF1AVDAC2SLC7A11CACNA2D1ALDH1A1 | |
| SCHEMBL4457976 | 0.86 | HIF1A (0.51) | HIF1AVDAC2SLC7A11CACNA2D1ALDH1A1 | |
| SCHEMBL4462685 | 0.86 | VDAC2 (0.73) | HIF1AVDAC2SLC7A11HTR7ALDH1A1 | |
| SCHEMBL13633582 | 0.85 | VDAC2 (0.72) | HIF1AVDAC2SLC7A11HTR7ALDH1A1 | |
| SCHEMBL13633630 | 0.85 | VDAC2 (0.78) | HIF1AVDAC2SLC7A11HTR7ALDH1A1 | |
| SCHEMBL12610180 | 0.85 | VDAC2 (0.68) | HIF1AVDAC2SLC7A11HTR7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2022212568-A9 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | 1BASE PHARMACEUTICALS, LLC (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2022212568-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | 1BASE PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20160271133-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | PROLEXYS PHARMACEUTICALS INC (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271133-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | PROLEXYS PHARMACEUTICALS INC (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160015710-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | PROLEXYS PHARMACEUTICALS INC (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160015710-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | PROLEXYS PHARMACEUTICALS INC (US) | 2016-01-21 | — | — | US | disclosed |
| US-20140227221-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | PROLEXYS PHARMACEUTICALS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140227221-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | PROLEXYS PHARMACEUTICALS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| WO-2009108384-A2 | COMPOUNDS AND COMPOSITIONS THAT CAUSE NON-APOPTOTIC CELL DEATH AND USES THEREOF | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| WO-2009002553-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | PROLEXYS PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20080299076-A1 | Compunds and compositions that cause non-apoptotic cell death and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| WO-2008013840-A2 | ERASTIN ANALOGS AND USES THEREOF | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008013840-A2 | ERASTIN ANALOGS AND USES THEREOF | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20070161644-A1 | Erastin analogs and uses thereof | STOCKWELL BRENT R | 2007-07-12 | — | — | US | disclosed |
| US-20070161644-A1 | Erastin analogs and uses thereof | STOCKWELL BRENT R | 2007-07-12 | — | — | US | disclosed |
| US-20070161644-A1 | Erastin analogs and uses thereof | STOCKWELL BRENT R | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271133-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | MCL1, SLC11A2, MEN1 | HIF1A 214/4885VDAC2 3099/4885SLC7A11 453/4885 |
| US-20080299076-A1 | Compunds and compositions that cause non-apoptotic cell death and uses thereof | BAD, CASP3, BAX | HIF1A 910/4885VDAC2 801/4885SLC7A11 2266/4885 |
| US-20070161644-A1 | Erastin analogs and uses thereof | ERAP2, ERAP1, ERAL1 | HIF1A 928/4885VDAC2 3980/4885SLC7A11 1250/4885 |
| US-20140227221-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | MCL1, BCL3, DDIT3 | HIF1A 275/4885VDAC2 4580/4885SLC7A11 1278/4885 |
| US-20160015710-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | MCL1, SLC11A2, MEN1 | HIF1A 214/4885VDAC2 3099/4885SLC7A11 453/4885 |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | HIF1A 726/4885VDAC2 553/4885SLC7A11 906/4885 |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | VDAC3, VDAC2, VDAC1 | HIF1A 2396/4885VDAC2 2/4885SLC7A11 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.